Close Menu

Pharmaceutical companies' interest in RNA interference is waning, says The New York Times' Andrew Pollack. Roche, Pfizer, and Abbott have all ceased to work on RNAi, though Roche's Klaus Stein says that he has "no doubt that at a certain point in time RNAi will make it to the market," but that there were "opportunities that have higher priorities" to focus on. Pollack adds that it is fairly common for a new technique to enjoy a moment of vogue before some interest in it is lost.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to Science, the US National Academy of Sciences is poised to eject two members accused of sexual harassment.

A UK study on mixing SARS-CoV-2 vaccines is expanding to include vaccines developed by additional companies, according to the Guardian.

In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.